W(h)ither the FDA?
By David Woods (david.woods@rxcomms.com) There has been much written lately about the perceived failings of the FDA. The Wall Street Journal claims that “the place is a mess,” and a…
DetailsHow to participate in or lead a panel discussion
By Mary Gabb (mary.gabb@rxcomms.com) As health economics plays a more prominent role in medical research and public policy, participation in panel discussions – either in front of a live audience…
DetailsHow to make sense of health economics
While economics is the main ingredient in most healthcare decisions today, health economics still has many pharmacologists, clinicians, physicians and marketing personnel left confused and appalled that quality of life…
DetailsTraining programmes: Where do future health economists come from?
By Robert Hand (robert.hand@rxcomms.com) For those interested in entering or advancing in the field of health economics and outcomes research, and for those looking for newly-minted researchers to employ, it…
DetailsHOC people: Patti Peeples Gustafson, PhD
By David Woods (david.woods@rxcomms.com) Dr. Patti Peeples: what a perfect name for the subject of HOC people! She tells me that the origin of the name is from Peebles, in…
DetailsDevelop a healthy scepticism about research even in the ‘best’ scientific journals
By David Woods (david.woods@rxcomms.com) The Wall Street Journal published an editorial last month titled “The Lancet’s Political Hit.” It described how that venerable medical journal had published a study exaggerating…
DetailsThe importance of the economic value message
The pharmaceutical industry faces the major issue of top selling drugs losing their patent protection, allowing generic products to replace them at much lower prices.
DetailsDealing with the media – confidently
By Julie Stauffer (julie.stauffer@rxcomms.com) The media can be a powerful vehicle for raising your profile, getting your message out and gaining credibility, but not everyone feels comfortable confronting a reporter’s…
DetailsIs big pharma becoming big biotech?
Recent reports in the Wall Street Journal and The Economist describe an imminent seismic shift in business models for pharmaceutical companies, as current blockbuster drugs are set to go off-patent and a rapidly dwindling pipeline of new drugs are under development or are being reviewed for approval.
DetailsHow to be a more effective public speaker
By Mary Gabb (mary.gabb@rxcomms.com) A frequently overlooked professional skill – especially among scientists – is public speaking, yet the inability to effectively communicate your work can place significant roadblocks in…
Details